These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12711173)

  • 1. The effect of formulation variables on the stability of nebulized aviscumine.
    Steckel H; Eskandar F; Witthohn K
    Int J Pharm; 2003 May; 257(1-2):181-94. PubMed ID: 12711173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of excipients on the stability and aerosol performance of nebulized aviscumine.
    Steckel H; Eskandar F; Witthohn K
    J Aerosol Med; 2003; 16(4):417-32. PubMed ID: 14977432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein.
    Steckel H; Eskandar F; Witthohn K
    Eur J Pharm Biopharm; 2003 Jul; 56(1):11-21. PubMed ID: 12837476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization.
    Ip AY; Arakawa T; Silvers H; Ransone CM; Niven RW
    J Pharm Sci; 1995 Oct; 84(10):1210-4. PubMed ID: 8801336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lyoprotection of aviscumine with low molecular weight dextrans.
    Gloger O; Witthohn K; Müller BW
    Int J Pharm; 2003 Jul; 260(1):59-68. PubMed ID: 12818810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers.
    Beck-Broichsitter M; Kleimann P; Schmehl T; Betz T; Bakowsky U; Kissel T; Seeger W
    Eur J Pharm Biopharm; 2012 Oct; 82(2):272-80. PubMed ID: 22820646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures.
    Elhissi AM; Faizi M; Naji WF; Gill HS; Taylor KM
    Int J Pharm; 2007 Apr; 334(1-2):62-70. PubMed ID: 17123757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers.
    Steckel H; Eskandar F
    Eur J Pharm Sci; 2003 Aug; 19(5):443-55. PubMed ID: 12907295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerosolization potential of cyclodextrins--influence of the operating conditions.
    Le VN; Leterme P; Gayot A; Flament MP
    PDA J Pharm Sci Technol; 2006; 60(5):314-22. PubMed ID: 17089700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilizing protein formulations during air-jet nebulization.
    Albasarah YY; Somavarapu S; Taylor KM
    Int J Pharm; 2010 Dec; 402(1-2):140-5. PubMed ID: 20933073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
    Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
    Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some factors associated with the ultrasonic nebulization of proteins.
    Niven RW; Ip AY; Mittelman S; Prestrelski SJ; Arakawa T
    Pharm Res; 1995 Jan; 12(1):53-9. PubMed ID: 7724488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.
    Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A
    Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design principles of liquid nebulization devices currently in use.
    Rau JL
    Respir Care; 2002 Nov; 47(11):1257-75; discussion 1275-8. PubMed ID: 12425742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
    Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
    Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.
    Kleemann E; Schmehl T; Gessler T; Bakowsky U; Kissel T; Seeger W
    Pharm Res; 2007 Feb; 24(2):277-87. PubMed ID: 17211729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. That's cool!--Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer.
    Hertel S; Pohl T; Friess W; Winter G
    Eur J Pharm Biopharm; 2014 Jul; 87(2):357-65. PubMed ID: 24662437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.
    Adler M; Langer M; Witthohn K; Wilhelm-Ogunbiyi K; Schöffski P; Fumoleau P; Niemeyer CM
    J Pharm Biomed Anal; 2005 Oct; 39(5):972-82. PubMed ID: 15982849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method.
    Hertel S; Pohl T; Friess W; Winter G
    Eur J Pharm Biopharm; 2014 Jul; 87(2):386-94. PubMed ID: 24709473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.